Virax Biolabs Group Limit... (VRAX)
undefined
undefined%
At close: undefined
2.39
-2.05%
After-hours Jan 03, 2025, 05:56 PM EST

Virax Biolabs Group Limited Statistics

Share Statistics

Virax Biolabs Group Limited has 4.34M shares outstanding. The number of shares has increased by 139.68% in one year.

Shares Outstanding 4.34M
Shares Change (YoY) n/a
Shares Change (QoQ) 0%
Owned by Institutions (%) n/a
Shares Floating 4.05M
Failed to Deliver (FTD) Shares 21.40K
FTD / Avg. Volume 1.18%

Short Selling Information

The latest short interest is 446.54K, so 10.28% of the outstanding shares have been sold short.

Short Interest 446.54K
Short % of Shares Out 10.28%
Short % of Float 11.01%
Short Ratio (days to cover) 0.11

Valuation Ratios

The PE ratio is -0.22 and the forward PE ratio is -1.09.

PE Ratio -0.22
Forward PE -1.09
PS Ratio 9.43
Forward PS 0.8
PB Ratio 0.27
P/FCF Ratio -0.2
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

Virax Biolabs Group Limited has an Enterprise Value (EV) of -1.81M.

EV / Earnings 0.27
EV / Sales -11.6
EV / EBITDA 0.27
EV / EBIT 0.28
EV / FCF 0.24

Financial Position

The company has a current ratio of 25.94, with a Debt / Equity ratio of 0.

Current Ratio 25.94
Quick Ratio 25.58
Debt / Equity 0
Total Debt / Capitalization 0
Cash Flow / Debt 0
Interest Coverage -241.7

Financial Efficiency

Return on equity (ROE) is -1.25% and return on capital (ROIC) is -121.13%.

Return on Equity (ROE) -1.25%
Return on Assets (ROA) -1.23%
Return on Capital (ROIC) -121.13%
Revenue Per Employee 9.20K
Profits Per Employee -396.09K
Employee Count 17
Asset Turnover 0.03
Inventory Turnover 1.75

Taxes

Income Tax 0
Effective Tax Rate 0

Stock Price Statistics

The stock price has increased by 92.13% in the last 52 weeks. The beta is 1.93, so Virax Biolabs Group Limited's price volatility has been higher than the market average.

Beta 1.93
52-Week Price Change 92.13%
50-Day Moving Average 1.99
200-Day Moving Average 1.71
Relative Strength Index (RSI) 61.58
Average Volume (20 Days) 1.81M

Income Statement

In the last 12 months, Virax Biolabs Group Limited had revenue of 156.42K and earned -6.73M in profits. Earnings per share was -3.36.

Revenue 156.42K
Gross Profit 50.59K
Operating Income -6.50M
Net Income -6.73M
EBITDA -6.61M
EBIT -6.50M
Earnings Per Share (EPS) -3.36
Full Income Statement

Balance Sheet

The company has 3.59M in cash and 224.30K in debt, giving a net cash position of 3.36M.

Cash & Cash Equivalents 3.59M
Total Debt 224.30K
Net Cash 3.36M
Retained Earnings -18.53M
Total Assets 5.48M
Working Capital 4.21M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -6.25M and capital expenditures -1.16M, giving a free cash flow of -7.41M.

Operating Cash Flow -6.25M
Capital Expenditures -1.16M
Free Cash Flow -7.41M
FCF Per Share -3.69
Full Cash Flow Statement

Margins

Gross margin is 3.23K%, with operating and profit margins of -415.32K% and -430.48K%.

Gross Margin 3.23K%
Operating Margin -415.32K%
Pretax Margin -430.84K%
Profit Margin -430.48K%
EBITDA Margin -4.23K%
EBIT Margin -4.15K%
FCF Margin -4.74K%

Dividends & Yields

VRAX does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield -137.7%
FCF Yield -69.96%
Dividend Details

Analyst Forecast

Currently there are no analyst rating for VRAX.

Price Target n/a
Price Target Difference n/a
Analyst Consensus n/a
Analyst Count n/a
Stock Forecasts

Stock Splits

The last stock split was on Dec 18, 2023. It was a backward split with a ratio of 1:10.

Last Split Date Dec 18, 2023
Split Type backward
Split Ratio 1:10

Scores

Altman Z-Score 2.01
Piotroski F-Score 3